Atacicept PDUFA preview: first dual BAFF/APRIL therapy approaches IgA nephropathy decision

On July 7, 2026, the FDA is expected to decide whether to approve atacicept, a dual BAFF and APRIL inhibitor developed by Vera Therapeutics, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. The Biologics License Application (BLA), submitted through the Accelerated Approval Program and granted priority review, seeks an indication based on proteinuria reduction demonstrated in the ORIGIN Phase 3 trial. If approved, atacicept would become the first B-cell modulator targeting both BAFF and APRIL pathways for IgAN, adding a new mechanism to a therapeutic area that has expanded rapidly since 2023.

This preview is for nephrology access teams, specialty pharmacy operators, payer medical directors, and market access professionals who need to understand atacicept's evidence base, competitive landscape, and potential access barriers ahead of the PDUFA date. It is not medical advice or reimbursement guidance for a specific patient or plan.

What atacicept is and how it works

Atacicept is a fully human recombinant fusion protein consisting of the extracellular ligand-binding portion of the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor linked to the Fc domain of human immunoglobulin G (IgG). It works by binding and neutralizing two key B-cell survival and differentiation factors:

1. B-cell activating factor (BAFF; also known as BLyS): A cytokine essential for B-cell survival, maturation, and immunoglobulin class switching.
2. A proliferation-inducing ligand (APRIL): A cytokine that promotes plasma-cell survival and immunoglobulin production, particularly IgA.

By simultaneously blocking BAFF and APRIL, atacicept reduces the production of galactose-deficient IgA1 (Gd-IgA1) — the central pathogenic molecule in IgA nephropathy — and decreases downstream immune-complex formation, complement activation, and glomerular inflammation. This mechanism targets the "four-hit" pathogenesis model of IgAN at its root: the overproduction of Gd-IgA1 by mucosal B cells.

Key parameters:

IgA nephropathy: the disease and treatment landscape

IgA nephropathy is the most common primary glomerular disease worldwide and a leading cause of chronic kidney disease and end-stage kidney disease (ESKD). The disease is characterized by deposition of immune complexes containing Gd-IgA1 in the glomerular mesangium, triggering inflammation, proteinuria, hematuria, and progressive loss of kidney function.

An estimated 25–30% of IgAN patients progress to ESKD within 20 years of diagnosis. The condition has historically been managed with renin-angiotensin system (RAS) blockade (ACE inhibitors or ARBs), corticosteroids (with significant toxicity concerns), and supportive care. Since 2023, the treatment landscape has expanded rapidly with FDA approvals of three disease-targeted therapies:

The U.S. IgAN market was valued at approximately $1.2 billion in 2025 and is projected to reach $8.1 billion by 2036, driven by earlier diagnosis, increasing treatment options, and a shift from supportive care to targeted therapy.

ORIGIN 3 Phase 3 trial results

Study design

ORIGIN 3 (NCT04716231) is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 431 adults with IgAN. Participants were randomized 1:1 to receive atacicept 150 mg or placebo, self-administered via once-weekly subcutaneous injection. All patients continued maximally tolerated RAS blockade.

Primary endpoint

The primary efficacy endpoint was the change in 24-hour urine protein-to-creatinine ratio (UPCR) compared to placebo at the prespecified 36-week interim analysis. ORIGIN 3 met the primary endpoint:

• 46% reduction in proteinuria from baseline ( atacicept arm)
• 42% reduction versus placebo (p < 0.0001)

The results were published in the New England Journal of Medicine in February 2026 and presented as a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2025.

Consistency of effects

Improvements were consistent across prespecified subgroups, including age, sex, race, geographic region, baseline proteinuria level, baseline eGFR, and concomitant SGLT2 inhibitor use.

Secondary endpoints

Extended follow-up through 96 weeks in the ORIGIN program showed:

• Continued Gd-IgA1 reduction
• Hematuria resolution
• Further proteinuria improvement
• Stabilization of kidney function as measured by eGFR

Safety

Across the ORIGIN program, atacicept's safety profile was described as favorable and comparable to placebo. Adverse events were generally mild to moderate. Notably, serum immunoglobulin levels (IgG, IgA, IgM) decreased following treatment initiation but stabilized after approximately 24 weeks. Atacicept has been administered to more than 1,500 patients across various clinical trials and disease areas, providing an extensive safety database.

Regulatory path

The BLA seeks accelerated approval based on the proteinuria surrogate endpoint. The confirmatory endpoint — change in eGFR over two years — continues to be evaluated in the ongoing ORIGIN 3 trial. On June 2, 2026, Vera Therapeutics announced FDA alignment on a revised, earlier eGFR analysis plan, with results now expected in Q3 2026. Pending positive eGFR data, Vera plans to submit a supplemental BLA (sBLA) for full approval in Q4 2026.

Competitive positioning

Atacicept vs. approved IgAN therapies

Key differentiators

1. Mechanistic breadth: Atacicept's dual BAFF/APRIL blockade targets both B-cell and plasma-cell pathways, potentially providing broader suppression of Gd-IgA1 production than APRIL-only agents like sibeprenlimab.
2. Self-administration: The autoinjector formulation enables at-home weekly dosing, which may improve adherence compared with monthly clinic-administered injections.
3. Pricing opportunity: ICER assessed atacicept's health-benefit price benchmark at $60,000–$80,000 per year — significantly below sibeprenlimab's current net price of $292,500 per year and potentially below Filspari's $160,000 per year. This pricing headroom could influence payer preference if Vera prices atacicept competitively.

ICER assessment

The Institute for Clinical and Economic Review (ICER) published its final evidence report on IgAN therapies in March 2026. Key findings:

• ICER's independent appraisal committee found that atacicept, sibeprenlimab, and Nefecon all provide a net health benefit rated "incremental or better" (B+) compared to no specific immunomodulatory therapy.
• Evidence was inadequate to assess comparative net health benefit among the three therapies against each other.
• ICER issued an access and affordability alert for sibeprenlimab at its current price.
• Atacicept's fair price range ($60,000–$80,000/year) represents a potential cost-effectiveness advantage over approved competitors.

Access implications

Prior authorization and step therapy

If approved, atacicept will enter a market where payers are already managing multiple IgAN therapies with distinct mechanisms and price points. Expected payer management strategies include:

• Prior authorization: Likely required by most commercial and Medicare Part D plans. Expected criteria: confirmed IgAN diagnosis with persistent proteinuria (UPCR ≥ 1.0 g/g) despite optimized RAS blockade, documented by kidney biopsy or clinical diagnosis.
• Step therapy: Some payers may require trial and failure of oral therapies (Tarpeyo or Filspari) before covering an injectable biologic. However, the distinct mechanism of action may support medical necessity exceptions.
• Formulary positioning: Atacicept's final pricing will heavily influence tier placement. If priced below sibeprenlimab, it may become the preferred BAFF/APRIL pathway agent on many formularies.

Specialty pharmacy considerations

• Atacicept will be dispensed through specialty pharmacy channels.
• Self-administered autoinjector reduces burden on infusion centers compared with IV-administered alternatives.
• Cold-chain requirements, patient training programs, and adherence monitoring will be standard components of the specialty pharmacy workflow.
• Hub services will likely include benefit verification, prior authorization support, copay assistance navigation, and patient education on self-injection technique.

Medicare Part D

As a Part D specialty drug, atacicept will be subject to the 2026 Part D benefit design, including the $2,100 annual out-of-pocket cap. If priced at $60,000–$80,000 per year, patients in the initial coverage phase would face significant cost-sharing before reaching the cap, making manufacturer copay assistance critical for commercially insured patients (who are ineligible for copay assistance under Medicare).

Launch readiness

Vera Therapeutics has signaled plans for a mid-2026 commercial launch pending approval. Matt Skelton, Chief Commercial Officer, is leading launch preparations. Key launch considerations include:

• Distribution network and specialty pharmacy partnerships
• Patient support program infrastructure (NovoCare-like hub model)
• Field reimbursement team deployment
• Early payer engagement and formulary submissions
• KOL and nephrology community education

What to monitor next

Source table

Sources

• Vera Therapeutics. "U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy." January 7, 2026. ir.veratx.com
• Vera Therapeutics. "Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial." 2025. ir.veratx.com
• Vera Therapeutics. "Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis." June 2, 2026. ir.veratx.com
• Lafayette R, et al. "A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy." N Engl J Med. 2026 Feb 12;394(7):647-657. ClinicalTrials.gov NCT04716231
• Institute for Clinical and Economic Review (ICER). "Final Evidence Report: Therapies for IgA Nephropathy." March 31, 2026. icer.org
• ICER. "IgA Nephropathy Patient Snapshot." February 2026. igan.org
• DelveInsight. "IgA Nephropathy (IgAN) Market Outlook and Forecast 2036." 2026. delveinsight.com
• Patient Worthy. "FDA Fast-Tracks Vera Therapeutics' Atacicept." January 30, 2026. patientworthy.com
• AJKD Blog. "#NephMadness 2026: IgA Nephropathy Region." March 2026. ajkdblog.org
• Spherix Global Insights. "Emerging Treatments Drive Notable Changes in IgA Nephropathy Care." 2026. spherixglobalinsights.com